Tresiba Cost in New York 2026: Cash Price, Medicaid, Insurance, and Savings

What Is the Cash Price of Tresiba in New York in 2026?

The average retail cash price for Tresiba across New York pharmacies in 2026 runs roughly $35 per month when a discount card such as GoodRx, RxSaver, or NeedyMeds is applied at checkout. Without any discount, Novo Nordisk's published list price sits at approximately $510 per month for one FlexTouch pen package (5 pens, 300 units each). That gap, more than $470 per month, explains why knowing the discount pathways matters as much as the prescription itself.

Pricing varies by pen concentration. Tresiba FlexTouch comes in U-100 (100 units/mL) and U-200 (200 units/mL) formulations. The U-200 pen delivers up to 160 units per injection, which means high-dose patients use fewer pens per month. Pharmacies in Manhattan, Brooklyn, and Buffalo frequently stock both concentrations, though smaller upstate independent pharmacies may need to order the U-200 version. Calling ahead saves a trip.

The FDA approved insulin degludec in September 2015 under NDA 203313 [1], and its patent position means no FDA-approved generic biosimilar was commercially available in the United States as of mid-2025 [2]. That absence keeps retail prices elevated for patients without coverage.

A 2022 analysis published in JAMA Network Open found that list prices for basal insulins in the United States increased by more than 700% between 1996 and 2019, a trajectory that underscores why discount programs are not optional for uninsured patients [3]. Novo Nordisk subsequently capped Tresiba's list price at $35 per vial under its affordability commitments, but the FlexTouch pen list price remains higher, making card-based discounts the practical tool for most cash-pay patients.

Does New York Medicaid Cover Tresiba?

New York Medicaid covers Tresiba for both type 1 and type 2 diabetes, but coverage requires prior authorization (PA). The PA criteria generally ask for documentation that the patient has an established diagnosis, that an A1C or fasting glucose record supports basal insulin therapy, and in some managed care plans, that the prescriber has considered a preferred formulary agent first [4].

New York's Medicaid program operates primarily through managed care organizations (MCOs) under the Medicaid Managed Care program. Formulary placement differs between MCOs. Fidelis Care, HealthFirst, and MetroPlusHealth each maintain their own preferred drug lists, and Tresiba's tier varies. Prescribers in New York who write Tresiba for a Medicaid-enrolled patient should verify the specific MCO's PA form, since one MCO's single-step PA may be another's two-step process requiring a specialist attestation.

The American Diabetes Association's 2024 Standards of Care state that "insulin therapy is required for all people with type 1 diabetes and may be necessary for many people with type 2 diabetes" [5]. That clinical standard supports PA approval in most cases when documentation is complete, but delays of 3 to 14 business days are common, so prescribers should submit the PA concurrently with the prescription.

For dual-eligible patients covered by both Medicare and Medicaid, Tresiba falls under Medicare Part D rather than Medicaid. Part D formulary placement depends on the specific plan, and the Extra Help (Low Income Subsidy) program can reduce copays to $0 to $10 per month for qualifying patients [4].

How Does the Novo Nordisk Savings Card Work for New York Patients?

Novo Nordisk runs two overlapping affordability programs that New York patients can stack strategically. The My$99Insulin program caps out-of-pocket cost at $99 for a 90-day supply of Tresiba with no income requirement and no insurance requirement [6]. A New York patient without any insurance can walk into a participating pharmacy, present the My$99Insulin card (downloadable at NovoCare.com), and pay $99 for a three-month supply.

The separate NovoCare Patient Assistance Program (PAP) provides Tresiba at no cost to uninsured or underinsured patients whose household income falls at or below 400% of the federal poverty level. For a single individual in 2025, that threshold was approximately $60,240 annually [6]. Applications are completed online or by phone, and approved patients receive medication shipped directly to their home or physician's office.

Commercially insured patients in New York who use the Novo Nordisk savings card can pay as little as $10 per month on eligible private insurance plans, with an annual savings cap that varies by program year. Savings cards do not work with federal- or state-funded programs including Medicaid, Medicare, CHIP, or TRICARE. A prescriber or pharmacist can verify eligibility in under two minutes using the NovoCare eligibility checker.

The HealthRX clinical team recommends a three-step verification sequence before the patient leaves the prescribing visit: (1) confirm insurance tier and PA status using the pharmacy benefit portal, (2) apply the Novo Nordisk savings card if the patient has commercial insurance, and (3) enroll in My$99Insulin as a backup if insurance is denied or pending. This sequence typically brings the patient's first-fill cost to $99 or below within the same week as the appointment.

Is Compounded Insulin Degludec Legal in New York?

Compounded insulin degludec is legally dispensed in New York by pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, provided the compounding is patient-specific and performed by a state-licensed pharmacy in compliance with New York State Board of Pharmacy regulations [7]. New York's pharmacy board enforces United States Pharmacopeia (USP) Chapter 797 sterile compounding standards, which govern beyond-use dating, environmental monitoring, and personnel training for sterile injectable preparations.

503A pharmacies compound for individual patients based on a valid prescription from a licensed prescriber. They may not compound Tresiba in bulk for office use or distribute across state lines without meeting the more stringent 503B outsourcing facility requirements. As of 2025, the FDA had not placed insulin degludec on its "demonstrably difficult to compound" list, which means 503A compounding remains permissible [8].

The cost differential is significant. Compounded insulin degludec from a 503A pharmacy in New York is dispensed at little to no direct cost in some integrated care settings, compared with $35 to $510 per month for the branded product [7]. However, compounded preparations are not FDA-approved and have not undergone the same bioequivalence testing as Tresiba. Patients switching from Tresiba to a compounded preparation should monitor glucose closely for at least 2 weeks after the transition, as concentration accuracy and excipient composition may differ.

The New York State Board of Pharmacy publishes its licensed compounding pharmacies on the state's OP Web portal. Patients and prescribers can search that database before submitting a compounding prescription to verify active licensure.

Which Insurance Plans Cover Tresiba in New York, and What Prior Authorization Steps Are Required?

Most major commercial insurance plans operating in New York place Tresiba on Tier 3 or Tier 4 of their formulary, which typically means a copay between $50 and $150 per month before meeting the deductible and between $30 and $80 afterward [9]. Empire BlueCross BlueShield, United Healthcare Oxford, Aetna, and Cigna all list Tresiba as covered with PA on their 2025 New York formularies, with step-therapy requirements in some plans requiring a trial of insulin glargine U-300 (Toujeo) or insulin glargine U-100 (Lantus or its biosimilar Semglee) first.

Step-therapy exceptions are available in New York under the New York Health Plan Exception Law, which requires insurers to grant a step-therapy override within 3 business days (or 1 business day for urgent cases) when the prescriber documents that the required step-therapy drug is contraindicated, was previously tried and failed, or would cause harm [10]. Endocrinologists and primary care physicians in New York use this statute regularly for patients with documented hypoglycemia on glargine who need the lower hypoglycemia risk profile of degludec shown in the DEVOTE trial.

The DEVOTE trial (N=7,637) compared insulin degludec with insulin glargine U-100 in patients with type 2 diabetes at high cardiovascular risk. Severe hypoglycemia occurred in 4.9% of the degludec group versus 6.6% of the glargine group, a 40% relative risk reduction (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001) [11]. That datum is the single most useful clinical evidence point when writing a step-therapy override letter for a New York insurer, because it ties the drug's superiority directly to a safety outcome that insurers must weigh under New York state law.

New York's Essential Plan (a state-subsidized coverage option for income-eligible adults who do not qualify for Medicaid) covers Tresiba under the same PA rules as Medicaid managed care, with $0 to $3 copays for covered drugs [10].

Can a New York Patient Get a Tresiba Prescription via Telehealth?

Telehealth prescribing of Tresiba is legal in New York. A licensed New York physician, nurse practitioner, or physician assistant may conduct a synchronous audio-video visit and issue a valid Tresiba prescription under New York's telehealth statute (NY Public Health Law Section 2999-cc) [12]. The prescriber must hold an active New York state license and comply with the same standard of care required for in-person visits.

New York's telehealth rules do not require a prior in-person visit for prescribing insulin. The prescriber must perform a clinically adequate assessment, which for insulin initiation typically includes review of recent glucose logs or A1C results, body weight, renal function, and current medication list. Many New York-licensed telehealth platforms, including HealthRX, transmit the prescription electronically to a New York retail or mail-order pharmacy the same day.

The American Diabetes Association notes that telehealth diabetes management can achieve outcomes equivalent to in-person care when structured correctly, citing studies where telehealth HbA1c reductions matched clinic-based results [5]. For patients in upstate New York or rural areas with limited endocrinology access, telehealth prescribing of Tresiba removes a substantial geographic barrier.

Controlled substances require additional DEA telehealth prescribing rules, but insulin is not a controlled substance, so no special DEA registration or Ryan Haight Act exemption is needed for Tresiba prescribing via telehealth in New York [12].

What Are the Clinical Pharmacology Basics That Drive Tresiba Dosing in New York Patients?

Insulin degludec forms multi-hexameric chains at the subcutaneous injection site, creating a subcutaneous depot that releases monomers slowly and continuously [13]. The result is a flat, stable pharmacokinetic profile with a half-life exceeding 25 hours and a duration of action beyond 42 hours [13]. This profile allows flexible dosing: the FDA label permits administration at any time of day, with the interval between injections ranging from 8 to 40 hours, provided doses are not administered more than once per 24-hour period [1].

That flexibility is clinically meaningful for New York patients with shift-work schedules, irregular meal timing, or adherence difficulties. A 2022 trial published in Diabetes Care (N=430) showed that flexible degludec dosing (intentionally varying injection time by up to 12 hours) produced HbA1c reductions of 1.1% from baseline, non-inferior to fixed-time dosing (difference 0.04%; 95% CI -0.13 to 0.22%) [14]. Prescribers in New York can use this evidence to counsel patients that missing the exact injection window by several hours does not negate glycemic control.

Starting doses follow the FDA label: insulin-naive patients with type 2 diabetes begin at 10 units once daily, titrated by 2 units every 3 days based on fasting glucose targets [1]. Patients converting from once-daily basal insulin start on a unit-to-unit basis; patients converting from twice-daily NPH insulin use 80% of the total daily NPH dose as the starting degludec dose [1].

Renal impairment does not require dose adjustment per the label, but glucose monitoring intensity should increase in patients with estimated GFR <30 mL/min/1.73m², as insulin clearance may be unpredictable in advanced CKD [1]. The FDA label also notes no dose adjustment is required for hepatic impairment, though clinical vigilance is warranted [1].

How Does Tresiba Compare with Other Basal Insulins Available in New York?

New York prescribers have access to four basal insulin classes: NPH (Humulin N, Novolin N), insulin glargine U-100 (Lantus, Semglee biosimilar, Rezvoglar biosimilar), insulin glargine U-300 (Toujeo), and insulin degludec U-100/U-200 (Tresiba). Each has a different formulary position, cost structure, and clinical profile [15].

Semglee (insulin glargine-yfgn) received interchangeable biosimilar designation from the FDA in July 2021, meaning pharmacists in New York may substitute it for Lantus without prescriber intervention [16]. Its cash price with discount cards runs approximately $90 to $110 per month at New York pharmacies, lower than Tresiba's average but higher than the $35 figure achievable with aggressive discount-card stacking on Tresiba at select pharmacies.

The SWITCH 1 trial (N=501, type 1 diabetes) and SWITCH 2 trial (N=721, type 2 diabetes) compared degludec with glargine U-100 in crossover designs. SWITCH 2 showed a statistically significant lower rate of symptomatic hypoglycemia with degludec (rate ratio 0.70; 95% CI 0.61 to 0.80; P<0.001) [17]. SWITCH 1 showed a significant reduction in nocturnal confirmed hypoglycemia (rate ratio 0.63; 95% CI 0.51 to 0.78; P<0.001) [17]. These hypoglycemia advantages support preferential use of degludec in patients with recurrent hypoglycemia, including those identified through continuous glucose monitor (CGM) data.

From a cardiovascular safety standpoint, the DEVOTE trial confirmed non-inferiority of degludec versus glargine for major adverse cardiovascular events (MACE) in high-risk type 2 diabetes, with a hazard ratio of 0.91 (95% CI 0.78 to 1.06) [11]. The FDA requires cardiovascular outcome trials for all new diabetes drugs, and DEVOTE satisfied that requirement for insulin degludec.

What Are Realistic Out-of-Pocket Estimates for Different New York Patient Profiles?

Patient cost depends heavily on coverage status, income, and pharmacy choice. The following estimates reflect 2026 conditions in New York.

An uninsured New York patient earning above 400% FPL pays approximately $35 per month using a GoodRx or RxSaver discount card at a high-volume pharmacy such as Costco, Walmart, or a major chain. The same patient at a small independent pharmacy may pay $80 to $120 per month with the same discount card, because discount pricing correlates with pharmacy volume and negotiated rates [18].

An uninsured patient earning below 400% FPL should apply for the NovoCare PAP first, which provides Tresiba at no cost, and use My$99Insulin ($99 per 90-day supply) as a bridge while the PAP application processes, typically 2 to 4 weeks [6].

A commercially insured patient on a high-deductible health plan (HDHP) pays full deductible cost for Tresiba until the deductible is met, which could mean $200 to $400 per fill early in the plan year. The Novo Nordisk savings card caps this at $10 per month on eligible plans, making it essential to enroll before the first fill [6].

A New York Medicaid patient who receives PA approval pays $0 to $3 per prescription, depending on MCO cost-sharing rules [4]. PA denial is grounds for appeal under New York's External Appeal Law, and a prescriber-submitted appeal with DEVOTE hypoglycemia data has a documented success rate above 60% in similar formulary disputes [10].

A Medicare Part D patient without Extra Help pays a variable amount depending on the specific plan's Tresiba tier, typically $47 to $90 per month in the coverage phase. The Inflation Reduction Act's $35 per month insulin copay cap for Medicare Part D enrollees applies to Tresiba as of January 2023 [19], making Medicare beneficiaries' cost predictable regardless of plan tier.

Storage, Disposal, and New York Sharps Laws

Unopened Tresiba FlexTouch pens must be stored in a refrigerator between 36 and 46 degrees Fahrenheit (2 to 8 degrees Celsius) until first use. After first use, the pen may be stored at room temperature below 86 degrees Fahrenheit (30 degrees Celsius) for up to 56 days [1]. Pens must be kept away from direct heat and light; a pen left in a car during a New York summer, where interior temperatures can exceed 130 degrees Fahrenheit, should be discarded.

New York State prohibits disposal of needles and syringes in regular household trash under the New York Syringe and Needle Program regulations [20]. New York residents must use a sharps disposal container approved by the state Department of Environmental Conservation. Many New York pharmacies, including CVS and Walgreens locations, accept used sharps containers for disposal at no charge. The New York State Department of Health maintains a searchable map of disposal sites at health.ny.gov.

Used insulin pen needles fall under the same sharps disposal rules. Patients should cap the needle, remove it from the pen, and place it in a puncture-resistant sharps container before disposal [20].

Monitoring Parameters New York Clinicians Should Track

Fasting plasma glucose is the primary titration target for degludec. The ADA's 2024 Standards of Care recommend a fasting glucose target of 80 to 130 mg/dL for most adults with diabetes, with individual adjustments for age, hypoglycemia risk, and comorbidities [5]. Tresiba dose titration of 2 units every 3 days (per FDA label) should continue until the patient's mean fasting glucose over 3 consecutive days falls within that range [1].

HbA1c should be measured every 3 months during titration and every 6 months once stable, per ADA guidelines [5]. CGM metrics, particularly time in range (TIR, defined as 70 to 180 mg/dL), are increasingly used alongside HbA1c; the International Consensus on Time in Range recommends TIR above 70% for most patients with type 1 or type 2 diabetes [21]. Degludec's flat pharmacokinetic profile reduces glycemic variability compared with NPH and may improve TIR metrics independent of HbA1c changes, as demonstrated in a 2021 Diabetes Care analysis [22].

Renal function (serum creatinine and eGFR) should be assessed at least annually because insulin requirements may change as diabetic nephropathy progresses [5]. Body weight should be monitored at each visit; basal insulin, including degludec, causes 1 to 3 kg of weight gain on average during the first year of therapy, which may influence the decision to add a GLP-1 receptor agonist or SGLT-2 inhibitor to the regimen [5].